Improved antigen cross-presentation by polyethyleneimine-based nanoparticles

Chen, Jian; Li, Zhengrong; Huang, Hong; Yang, Yanzhu; Ding, Qi; Mai, Junhua; Guo, Wei; Yang, Xu

doi:10.2147/ijn.s15457

Cited by 64 publications

(49 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have exploited the ability of PEI to promote cross-presentation through the MHC Class I pathway (105,106). Treatment of mice with PEI complexed DNA encoding for OVA resulted in antigen-specific target cell lysis and activation of B3Z cells (OVA/Kb-specific CD8+ cytotoxic T cell clone that recognizes the target cells through the class I MHC molecules), indicative of greater rates of OVA cross-presentation (106).…”

Section: Synthetic Polymer-based Particlesmentioning

confidence: 99%

Biomaterials for Nanoparticle Vaccine Delivery Systems

2014

View full text Add to dashboard Cite

Subunit vaccination benefits from improved safety over attenuated or inactivated vaccines, but their limited capability to elicit long-lasting, concerted cellular and humoral immune responses is a major challenge. Recent studies have demonstrated that antigen delivery via nanoparticle formulations significantly improve immunogenicity of vaccines due to either intrinsic immunostimulatory properties of the materials or by co-entrapment of molecular adjuvants such as Toll-like receptor agonists. These studies have collectively shown that nanoparticles designed to mimic biophysical and biochemical cues of pathogens offer new exciting opportunities to enhance activation of innate immunity and elicit potent cellular and humoral immunity with minimal cytotoxicity. In this review, we present key research advances that were made within the last 5 years in the field of nanoparticle vaccine delivery systems. In particular, we focus on the impact of biomaterials composition, size, and surface charge of nanoparticles on modulation of particle biodistribution, delivery of antigens and immunostimulatory molecules, trafficking and targeting of antigen presenting cells, and overall immune responses in systemic and mucosal tissues. This review describes recent progresses in the design of nanoparticle vaccine delivery carriers, including liposomes, lipid-based particles, micelles and nanostructures composed of natural or synthetic polymers, and lipid-polymer hybrid nanoparticles.

show abstract

Section: Synthetic Polymer-based Particlesmentioning

confidence: 99%

Biomaterials for Nanoparticle Vaccine Delivery Systems

2014

View full text Add to dashboard Cite

show abstract

“…40 Furthermore, PEI delivers proteins into cells and facilitates protein release from the endosome toward the MHC I pathway. [41][42][43] Therefore, we propose that LPPC delivers proteins into cells resulting in the exogenous antigen becoming an endogenous antigen that is processed and presented on MHC I molecules.…”

Section: Discussionmentioning

confidence: 99%

Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch

Chen

Lin

Liu

et al. 2012

IJN

View full text Add to dashboard Cite

Abstract:The aim of vaccination is to induce appropriate immunity against pathogens. Antibody-mediated immunity is critical for protection against many virus diseases, although it is becoming more evident that coordinated, multifunctional immune responses lead to the most effective defense. Specific antibody (Ab) isotypes are more efficient at protecting against pathogen invasion in different locations in the body. For example, compared to other Ab isotypes, immunoglobulin (Ig) A provides more protection at mucosal areas. In this study, we developed a cationic lipopolymer (liposome-polyethylene glycol-polyethyleneimine complex [LPPC]) adjuvant that strongly adsorbs antigens or immunomodulators onto its surface to enhance or switch immune responses. The results demonstrate that LPPC enhances uptake ability, surface marker expression, proinflammatory cytokine release, and antigen presentation in mouse phagocytes. In contrast to Freund's adjuvant, LPPC preferentially activates Th1-immunity against antigens in vivo. With lipopolysaccharides or CpG oligodeoxynucleotides, LPPC dramatically enhances the IgA or IgG2A proportion of total Ig, even in hosts that have developed Th2 immunities and high IgG1 serum titers. Taken together, the results demonstrate that the LPPC adjuvant not only increases the immunogenicity of antigens but also modulates host immunity to produce an appropriate Ab isotype by combining with immunomodulators.

show abstract

“…ovalbumin via the MHC class I pathway in mouse bone marrow derived dendritic cells, and these dendritic cells were found to stimulate IL-2 secretion in RF33.70 cells [111].…”

Section: Liposomesmentioning

confidence: 95%

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

Patravale¹,

Prabhu²

2014

Nanocarriers

View full text Add to dashboard Cite

Vaccination has indubitably made noteworthy contribution to global health. Recent years have witnessed the employment of subunit antigens rather than inactivated or live attenuated vaccines, owing to the superior safety of the former. The intrinsic weak immunogenicity of subunit antigens makes it imperative to formulate them with an adjuvant. Presently, the armamentarium of approved vaccine adjuvants is very poor. Nanocarriers hold great promise for successful vaccine delivery owing to their versatility, excellent cellular uptake properties, capacity to protect antigen, amenability to targeting, and ability to offer prolonged antigen presentation. All these attributes ultimately endow nanocarriers with immense potential to achieve needle-free vaccine delivery, reduce the number of vaccinations, attain dose sparing of antigen, and lead to stronger immune response generation. Nanocarriers can be explored in manifold ways to accomplish targeted antigen delivery to antigen presenting cells. They can be formulated to contain both antigen and immunostimulant molecules, and they can be engineered from specific materials to achieve antigen presentation through the desired pathway to stimulate a particular arm of the immune response. This review discusses the basics of immune response generation, mechanisms of adjuvanticity by nanocarriers, parameters influencing their adjuvanticity, and finally describes the incredible opportunities offered by a gamut of nanocarriers for vaccine delivery.

show abstract

Improved antigen cross-presentation by polyethyleneimine-based nanoparticles

Cited by 64 publications

References 33 publications

Biomaterials for Nanoparticle Vaccine Delivery Systems

Biomaterials for Nanoparticle Vaccine Delivery Systems

Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

Contact Info

Product

Resources

About